BiotechTube

TBI-1401(HF10) + Ipilimumab

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Melanoma Stage III

Conditions

Melanoma Stage III, Melanoma Stage IV

Trial Timeline

May 25, 2017 → Dec 14, 2018

NCT ID
NCT03153085

About TBI-1401(HF10) + Ipilimumab

TBI-1401(HF10) + Ipilimumab is a phase 2 stage product being developed by Takara Bio for Melanoma Stage III. The current trial status is completed. This product is registered under clinical trial identifier NCT03153085. Target conditions include Melanoma Stage III, Melanoma Stage IV.

What happened to similar drugs?

4 of 20 similar drugs in Melanoma Stage III were approved

Approved (4) Terminated (2) Active (14)
✅dabrafenib + trametinibNovartisApproved
✅ZelborafRocheApproved
✅Nivolumab + RelatlimabBristol Myers SquibbApproved
✅Fibrin Sealant (Tisseel) used in the Experimental Arm.BaxterApproved
❌Tasisulam-sodium + PaclitaxelEli LillyPhase 3
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03153085Phase 2Completed

Competing Products

20 competing products in Melanoma Stage III

See all competitors
ProductCompanyStageHype Score
mRNA-4157 + PembrolizumabMerckPhase 2
39
AVT32-DRL_PB + KeytrudaDr. Reddy's LaboratoriesPhase 1
33
Binimetinib Oral TabletBiotrialPhase 1
15
Tasisulam-sodium + PaclitaxelEli LillyPhase 3
32
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT01 + [68Ga]VMT02Perspective TherapeuticsPhase 1
23
FYB206 + KeytrudaFormycon AGPhase 1
23
PLX3397Daiichi SankyoPre-clinical
26
PLX3397 + PembrolizumabDaiichi SankyoPhase 1/2
24
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
DS-8273a + NivolumabDaiichi SankyoPhase 1
29
PLX3397 + vemurafenibDaiichi SankyoPhase 1
21
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
42
CP-461Astellas PharmaPhase 2
27
YM155Astellas PharmaPhase 2
35
YM155 + DocetaxelAstellas PharmaPhase 2
35
Denileukin diftitoxEisaiPhase 2
35
E7080EisaiPhase 1
29
lenvatinib + pembrolizumabEisaiPhase 2
35
MORAb-004 (monoclonal antibody)EisaiPhase 2
35